Compare BridgeBio Pharma Inc (BBIO) vs Zeta Global Holdings Corp (ZETA) Price & Performance

BridgeBio Pharma (BBIO) trades at $84.57, down slightly by 0.12% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 revenue growth driven by Attruby sales, though it missed EPS estimates. With a high P/S ratio of 22.77 and negative profitability metrics, the stock is priced for future growth, supported by strong analyst buy ratings and a $104.56 consensus price target.

The outlook hinges on successful product launches and regulatory approvals, with three potential launches expected within 12 months offering significant upside. Key risks include persistent cash burn, high debt, and execution challenges in bringing new treatments to market, which could pressure the stock if milestones are missed.

ZETA stock trades at $28.62, up 3.92% in the past 24 hours, with a bullish technical signal from moving averages and strong support at $28. The company reported its 20th consecutive beat-and-raise quarter in Q2 2026, with revenue up 44% year-over-year and achieving its first GAAP net income. Analyst consensus is strongly bullish with a $30.44 price target, and recent news highlights AI-driven growth and a partnership with Palantir.

The outlook for ZETA is positive due to robust revenue growth, expanding AI adoption, and improving profitability, but risks include a rich valuation with a P/S of 4.35 and EV/EBITDA of 95.89, execution challenges in integrating acquisitions, and competitive pressures in the marketing tech sector. The stock's proximity to its 52-week high suggests limited near-term upside without continued strong earnings performance.